#Israel #Clinical Trial #pancreatic cancer #Amorphical #Nes Ziona

Amorphical's Breakthrough Approach to Treating Stage IV Pancreatic Cancer

Amorphical, a pioneer in nano-amorphous mineral-based pharmacological agents, has made a significant advancement in cancer treatment by enrolling its first patient in a Phase 2 clinical trial. This trial investigates a novel therapy specifically designed for patients with stage IV pancreatic cancer, a notoriously aggressive and deadly form of cancer.

The Challenge of Pancreatic Cancer

Every year, nearly 496,000 individuals worldwide receive a diagnosis of pancreatic cancer. With an alarming five-year survival rate of below 13%, and a meager 3% for those facing advanced stages, it is clear that new treatment options are desperately needed. Advanced pancreatic cancer is characterized by acidic tumor microenvironments that hinder effective treatment and immune responses, leading to rapid disease progression.

Introducing a New Therapeutic Hope

Amorphical's investigational therapy focuses on addressing the unique challenges posed by tumor acidity. By utilizing nano-amorphous mineral technology, the aim is to selectively buffer the tumor's acidic environment. This approach hopes to restore immune system functionality, decrease tumor aggressiveness, and enhance the overall effectiveness of standard treatments.

The study is under the vigilant oversight of the Helsinki Committee of Shaare Zedek Medical Center and has received approval from the Israel Ministry of Health. It seeks to determine the therapy's ability to extend patients' progression-free survival (PFS), overall survival (OS), response rate (ORR), and overall quality of life.

Insights from Leading Experts

Dr. Ofer Purim, the Director of the Gastrointestinal Tumors Service at Shaare Zedek Medical Center and lead investigator for the trial, articulated the urgency of finding innovative therapies for pancreatic cancer. He stated, "Our goal is to investigate whether Amorphical's nano-amorphous mineral-based therapy can extend patient survival and improve quality of life for those with this aggressive disease."

The clinical trial is a continuation of Amorphical's extensive preclinical research findings, which indicate the technology's potential in addressing pathological acidity—one of the key players in tumor growth.

Eden Ben, Chief Executive Officer of Amorphical, emphasized the significance of this milestone, stating, "First patient enrollment in this trial marks an important milestone for Amorphical and for patients battling one of the toughest cancers. Our vision is to harness the unique properties of our nano-amorphous mineral technology to address the acidic tumor microenvironment, with the ultimate goal of extending life for patients with Stage IV pancreatic cancer."

A Decade of Progress

Amorphical's journey into clinical development has been bolstered by over ten years of real-world exposure through early access and compassionate use programs, which have provided valuable insights into treatment safety and tolerability.

In addition to its work on pancreatic cancer, Amorphical is also advancing research in several other conditions, including hypoparathyroidism, Crohn's disease, and osteoporotic fractures. Currently, the company's therapeutic platform is protected by an impressive portfolio of more than 190 patents across the globe.

As the Phase 2 trial unfolds, the medical community eagerly anticipates the data expected in the third quarter of 2026, hopeful for more advancements in the fight against pancreatic cancer. For more details about Amorphical and its innovative therapies, visit www.amorphical.com.